sgTP53_3 Citations (1)
Originally described in: Integrated genetic and pharmacologic interrogation of rare cancers.Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, Kryukov GV, Clemons PA, Tsherniak A, Vazquez F, Crompton BD, Shamji AF, Rodriguez-Galindo C, Janeway KA, Roberts CW, Stegmaier K, van Hummelen P, Cima MJ, Langer RS, Garraway LA, Schreiber SL, Root DE, Hahn WC, Boehm JS Nat Commun. 2016 Jun 22;7:11987. doi: 10.1038/ncomms11987. PubMed Journal
Articles Citing sgTP53_3
| Articles |
|---|
| Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Huerga Sanchez I, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Cancer Cell. 2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. Epub 2024 Oct 10. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.